Luspatercept

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-06-03 — A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib: cross-connection with elritercept-mf-anemia: Both are TGF-β superfamily ligand traps targeting MF-associated anemia on a ruxolitinib backbone; elritercept’s late-phase placebo-controlled trial parallels luspatercept’s anemia indication and provides comparator context for the ligand-trap class. (novelty: 3)
• 2026-02-05 — A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis: cross-connection with elritercept-myelofibrosis: Both are TGF-β superfamily ligand traps targeting anemia in MPN/MF; elritercept extends this mechanistic class with monotherapy and ruxolitinib-combination evaluation in MF. (novelty: 4)
• 2026-04-20 — Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis: cross-connection with luspatercept-mpn-posttransplant: Same molecule (luspatercept) being studied in a distinct indication — post-HSCT erythroid engraftment failure prevention vs. MPN-associated anemia outside transplant context. (novelty: 4)
• 2026-04-20 — Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis: Phase 2 trial (early-stage) is testing luspatercept added to momelotinib in transfusion-dependent MF patients (JAKi-naïve or experienced), pairing TGF-β ligand trap-mediated erythroid maturation with JAK1/2+ACVR1 inhibition as a dual-mechanism anemia strategy. (novelty: 3)

Open questions

Related